Evidence map›Paper›PMID 30974899›Full record

ArticleCancers2019

Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes.

Stephanie Bridgeman, Wendy Northrop, Gaewyn Ellison, Thiru Sabapathy, Phillip E Melton, Philip Newsholme, Cyril D S Mamotte

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stephanie BridgemanSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. stephanie.allen@postgrad.curtin.edu.au.ORCID 0000-0002-8399-5458
Wendy NorthropSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. wendy.northrop@student.curtin.edu.au.
Gaewyn EllisonSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. gaewyn.ellison@postgrad.curtin.edu.au.ORCID 0000-0002-5382-4519
Thiru SabapathySchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. t.sabapathy@postgrad.curtin.edu.au.
Phillip E MeltonSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. phillip.melton@curtin.edu.au.ORCID 0000-0003-4026-2964
Philip NewsholmeSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. Philip.Newsholme@curtin.edu.au.
Cyril D S MamotteSchool of Pharmacy and Biomedical Sciences, and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia. c.mamotte@curtin.edu.au.
Curtin University · AUThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential anticancer effects of statins-a widely used class of cholesterol lowering drugs-has generated significant interest, as has the use of epigenetic modifying drugs such as HDAC and DNMT inhibitors. We set out to investigate the effect of statin drugs on epigenetic modifications in multiple cell lines, including hepatocellular carcinoma, breast carcinoma, leukemic macrophages, cervical adenocarcinoma, and insulin-secreting cells, as well as liver extracts from statin-treated C57B1/6J mice. Cells or cell extracts were treated with statins and with established epigenetic modulators, and HDAC, HAT, and DNMT activities were quantified. We also examined histone acetylation by immunoblotting. Statins altered neither HDAC nor HAT activity. Accordingly, acetylation of histones H3 and H4 was unchanged with statin treatment. However, statins tended to increase DNMT activity. These results indicate that direct inhibition of the major classes of epigenetic modifying enzymes, as previously reported elsewhere, is unlikely to contribute to any anticancer effects of statins. This study concerned global effects on epigenetic enzyme activities and histone acetylation; whether statins influence epigenetic modifications in certain genomic regions, cannot be ruled out and remains to be investigated.

Indexed as

DNA methylationDNMT inhibitorsepigeneticsHDAC inhibitorshistone acetylationHMG-CoA reductase inhibitors

Identifiers

PMID30974899
PMCPMC6521159
OpenAlexW2939707088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.